Abbott Laboratories (NYSE:ABT) currently has a daily average trading volume of 5.75M but it saw 4096583 shares traded in last market. With a market cap of 184.43B USD, the company’s current market price of $106.29 came rising about 0.30 while comparing to the previous closing price of $105.97. In past 52 weeks, the stock remained buoying in the range of price level as high as $121.64 and as low as $89.67.
Taking a look at 20-day trading activity of Abbott Laboratories (ABT) gives us an average price of $108.40, while its current price level is -12.62% below from 52-week high level whereas it is 18.53% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $113.16 while that of 200 days or SMA-200 reads an average of $106.68. A closer look into the stock’s movement over the week reveals that its volatility is standing at 1.24% during that period while stretching the period over a month that increases to 1.68%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 37.49 which implies that the stock is in neutral territory.
Morgan Stanley downgraded its recommendation for the stock as a “Equal-Weight” from “Overweight” on May 30, 2023 while assigning a price target of $112. Wolfe Research issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $107 and $103.
Over the week, ABT’s stock price is moving -0.56% down while it is -5.12% when we observe its performance for the past one month. Year-to-date it is -3.43% down and over the past year, the stock is showing a downside performance of -4.34%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of 1.08 beat the consensus estimate of 1.05 for the same. In next quarter, company is expected to be making quarterly sales of $10.56B as analysts are expecting the sales for current fiscal year at $41.74B and seeing the company making $44.77B in sales next year. Moreover, analysts are in estimates of $10.37B for current-quarter revenue.
Currently, Abbott Laboratories’s total number of outstanding shares is 1.73B. Company’s return on investment (ROI) stands at 10.56% and return on equity (ROE) at 15.15%. It has a price to earnings ratio (P/E ratio) of 33.08 while having a 20.67 of forward P/E ratio. Stock’s beta reads 0.75. Stock has a price to book (P/B) ratio of 4.77 while price to sale or P/S ratio amounts to 4.57. Its return on asset (ROA) is 7.72% on average.
